Frequently Asked Questions
Nanotherapeutics is the branch of nanomedicine that focuses on using nanotechnology to develop therapeutic agents, such as nanoparticles and nanodevices, for targeted drug delivery, improved efficacy, and reduced side effects in treating various diseases.
Key factors include the rising prevalence of chronic diseases, advancements in targeted drug delivery technologies, increasing R&D investments, growing demand for personalized medicine, and supportive government initiatives for nanotechnology research.
The Nanotherapeutics market is projected to grow from USD 235.88 billion in 2025 to USD 724.45 billion by 2035.
The market is expected to achieve a CAGR of 12.0% during the forecast period from 2026 to 2035.
North America will contribute notably, holding approximately 42% of the market share due to its advanced healthcare infrastructure and high R&D investments.
Major players include Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Novartis AG, Abbott Laboratories, Bristol-Myers Squibb, Moderna, Inc., Nanobiotix, Celgene Corporation (BMS), and Sanofi.
The report provides comprehensive analysis including market size, trends, segmentation, regional insights, key players, growth drivers, restraints, opportunities, and forecasts from 2026 to 2035.
The value chain includes raw material sourcing, nanoparticle synthesis and formulation, preclinical testing, clinical trials, regulatory approval, manufacturing, distribution, and end-user application in healthcare settings.
Trends are shifting toward personalized and theranostic nanomedicines, with consumers preferring minimally invasive, targeted therapies that offer higher efficacy and fewer side effects in treatments for cancer and chronic diseases.
Regulatory factors include stringent FDA approval processes for safety and efficacy, while environmental concerns involve the potential toxicity of nanoparticles and the need for sustainable, biodegradable materials to minimize ecological impact.